J. Wagner

J. Wagner, Chengcheng Liu, A. Mehta, 2013, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

G. Herman, J. Wagner, K. Lasseter, 2008, Journal of clinical pharmacology.

MK-0448, a Specific Kv1.5 Inhibitor: Safety, Pharmacokinetics, and Pharmacodynamic Electrophysiology in Experimental Animal Models and Humans

W. Kraft, H. Greenberg, C. Regan, 2012, Circulation. Arrhythmia and electrophysiology.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers

P. Rothenberg, J. Wagner, K. Gottesdiener, 2008, Journal of clinical pharmacology.

Effect of Low‐, Moderate‐, and High‐Fat Meals on Raltegravir Pharmacokinetics

J. Chodakewitz, J. Wagner, D. Brainard, 2011, Journal of clinical pharmacology.

Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children.

P. Walson, J. Connor, C. Matthews, 2011, Clinical therapeutics.

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

G. Herman, A. Bergman, J. Wagner, 2009, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment

J. Wagner, R. Lalonde, J. Wagner, 2009, Clinical pharmacology and therapeutics.

Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.

J. Wagner, S. Ramael, K. Gottesdiener, 2013, British journal of clinical pharmacology.

Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine

J. Chandler, J. Wagner, J. Simon, 2014, Menopause.

Effects of Age, Sex, and Obesity on the Single‐Dose Pharmacokinetics of Omarigliptin in Healthy Subjects

D. Tatosian, E. Kauh, J. Wagner, 2016, Clinical pharmacology in drug development.

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

D. Tatosian, J. Wagner, R. Krishna, 2016, Journal of clinical pharmacology.

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

D. Rader, D. Connolly, Jiajun Liu, 2012, Science Translational Medicine.

Bioavailability of Alendronate and Vitamin D3 in an Alendronate/Vitamin D3 Combination Tablet

R. Ramakrishnan, J. Wagner, E. Woolf, 2011, Journal of clinical pharmacology.

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

L. V. Van Bortel, J. Wagner, K. Lasseter, 2013, British journal of clinical pharmacology.

Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment

J. Wagner, K. Lasseter, T. Marbury, 2011, Journal of clinical pharmacology.

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

J. Wagner, K. Lasseter, R. Robson, 2009, Antimicrobial Agents and Chemotherapy.

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor

J. Wagner, E. Rubin, N. Agrawal, 2013, Cancer Chemotherapy and Pharmacology.

A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer

Jaclyn K Patterson, P. Munster, J. Wagner, 2009, Clinical Cancer Research.

Lack of Effect of Antacids on Single‐Dose Pharmacokinetics of Etoricoxib

M. Guillaume, J. Wagner, J. Schwartz, 2007, Journal of clinical pharmacology.

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.

E. O'Mara, J. Wagner, J. Butterton, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, J. Wagner, B. Nguyen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

H. Teppler, J. Wagner, K. Lasseter, 2008, Antimicrobial Agents and Chemotherapy.

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

H. Greenberg, J. Wagner, K. Gottesdiener, 2008, Antimicrobial Agents and Chemotherapy.

The FNIH Biomarkers Consortium embraces the BEST

C. Austin, L. Brady, J. Menetski, 2019, Nature Reviews Drug Discovery.

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.

D. Tatosian, C. Matthews, Diana Selverian, 2016, Clinical therapeutics.

Multiple‐Dose Administration of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Alter the Single‐Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects

G. Herman, A. Bergman, J. Wagner, 2007, Journal of clinical pharmacology.

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.

G. Herman, A. Bergman, J. Wagner, 2008, British journal of clinical pharmacology.

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.

S. Heymsfield, D. Macneil, Haiyuan Zhu, 2007, The Journal of clinical endocrinology and metabolism.

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

G. Herman, A. Bergman, J. Wagner, 2009, Journal of clinical pharmacology.

Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans

J. Chodakewitz, D. Dean, Sanjeev Kumar, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [ 14 C ] Sitagliptin in Humans

W. Zeng, S. Xu, G. Herman, 2007 .

Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans

W. Zeng, S. Xu, G. Herman, 2007, Drug Metabolism and Disposition.

The failure to fail smartly

Lynn D. Hudson, R. Califf, J. DiMasi, 2020, Nature Reviews Drug Discovery.

Laropiprant in Combination With Extended‐Release Niacin Does Not Alter Urine 11‐Dehydrothromboxane B2, a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

Jaclyn K Patterson, O. Laterza, J. Wagner, 2009, Journal of clinical pharmacology.

Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib.

M. Wehling, J. Wagner, J. Schwartz, 2008, British journal of clinical pharmacology.

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

T. Rushmore, H. Greenberg, E. Carlini, 2009, Clinical pharmacology and therapy.

Multiple‐Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, in Healthy Male Volunteers

P. Rothenberg, J. Wagner, K. Gottesdiener, 2008, Journal of clinical pharmacology.

Innovations driving biomarker evaluation and use.

J. Wagner, 2010, Biomarkers in medicine.

Pharmacokinetics of Laropiprant and Glucuronide Metabolite in Patients with Severe Renal Insufficiency

J. Wagner, J. Stone, M. Stroh, 2009, American journal of therapeutics.

Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

Viswanath Devanarayan, Russell Weiner, Chad Ray, 2006, Pharmaceutical Research.

Bridging Preclinical and Clinical Development: Biomarker Validation and Qualification

J. Wagner, 2006 .

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

J. Wagner, T. Marbury, K. Gottesdiener, 2008, Journal of clinical pharmacology.

The minimal impact of food on the pharmacokinetics of ridaforolimus

J. Wagner, M. Trucksis, D. Panebianco, 2012, Cancer Chemotherapy and Pharmacology.

Quantifying monocyte infiltration in response to intradermal tetanus toxoid injection.

P. Rothenberg, J. Demartino, J. Wagner, 2012, Biomarkers in medicine.

Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor

L. Sepp-Lorenzino, J. Wagner, N. Agrawal, 2015, Cancer Chemotherapy and Pharmacology.

Use of Healthy Volunteers Drives Clinical Oncology Drug Development Decision Making

J. Wagner, R. Iannone, M. Iwamoto, 2012, Clinical pharmacology and therapeutics.

Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.

J. Wagner, 1999, Current opinion in molecular therapeutics.

PIII‐60

W. Zeng, W. Smith, G. Herman, 2006 .

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study

E. Sellers, J. Wagner, J. McCrea, 2016, Journal of clinical psychopharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D 2 Receptor

H. Greenberg, K. Metters, J. Wagner, 2007 .

A dynamic map for learning, communicating, navigating and improving therapeutic development

Lynn D. Hudson, R. Altman, S. Terry, 2018, Nature Reviews Drug Discovery.

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

D. Rader, S. Previs, B. Hubbard, 2017, Arteriosclerosis, thrombosis, and vascular biology.

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist

J. Chodakewitz, J. Wagner, P. Jumes, 2009, Journal of clinical pharmacology.

A Pharmacokinetic Comparison of Adult and Paediatric Formulations of Raltegravir in Healthy Adults

M. Rizk, J. Wagner, Elizabeth G. Rhee, 2014, Antiviral therapy.

Clinical Pharmacology Profile of Raltegravir, an HIV‐1 Integrase Strand Transfer Inhibitor

J. Wagner, D. Brainard, J. Stone, 2011, Journal of clinical pharmacology.

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

J. Wagner, K. Gottesdiener, J. Stone, 2009, Antimicrobial Agents and Chemotherapy.

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

J. Wagner, K. Lasseter, S. Ramael, 2008, Clinical pharmacology and therapeutics.

Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist

J. Wagner, Nicole Lewis, S. Dunbar, 2009, Advances in therapy.

Influence of Taranabant, an Orally Active, Highly Selective, Potent Cannabinoid‐1 Receptor (CB1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics

J. Wagner, K. Lasseter, J. Schwartz, 2009, Journal of clinical pharmacology.

Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study

P. Winner, J. Wagner, S. Stoch, 2012, Headache.

Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration.

J. Wagner, A. Mehta, S. Stoch, 2013, International journal of clinical pharmacology and therapeutics.

Brain CB-1 receptor occupancy of taranabant in lean subjects using CB-1R PET

P. Dupont, L. Mortelmans, G. Bormans, 2007 .

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

W. Zeng, G. Herman, A. Bergman, 2007, Biopharmaceutics & drug disposition.

Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist

A. Hartford, B. Cirincione, J. Wagner, 2010, The AAPS Journal.

Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin

E. O'Mara, J. Wagner, J. Butterton, 2013, Antimicrobial Agents and Chemotherapy.

Taranabant, a Novel Cannabinoid-1 Receptor Inverse Agonist, Increases Energy Expenditure in Overweight and Moderately Obese Subjects

S. Heymsfield, J. Wagner, K. Gottesdiener, 2007 .

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

A. Tolcher, K. Papadopoulos, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

W. Bridson, J. Wagner, K. Gottesdiener, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.

Sandra M. Sanabria-Bohórquez, E. Ravussin, S. Heymsfield, 2008, Cell metabolism.

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.

G. O'neill, F. Liu, J. Wagner, 2007, Clinical pharmacology and therapeutics.

Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects

L. V. Van Bortel, J. Wagner, J. Butterton, 2015, Antiviral therapy.

A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects

Derek Blair, J. Wagner, G. Smithson, 2021, Clinical and translational science.

The Patient‐Centered Future of Clinical Pharmacology

Mohamed H. Shahin, K. Morrissey, Julie A. Johnson, 2019, Clinical pharmacology and therapeutics.

Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor

C. Hawkey, S. Waldman, L. DeTora, 2003, Journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

W. Zeng, G. Herman, A. Bergman, 2005, Clinical pharmacology and therapeutics.

Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients

I. Pike, J. Wagner, D. R. van Harken, 1997, Antimicrobial agents and chemotherapy.

Safety and Antiviral Activity of MK-5172, a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients

R. Nachbar, J. Wagner, D. Brainard, 2010 .

Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity*

John A Wagner, Margaret S. Wu, T. Buchanan, 2004, Journal of Biological Chemistry.

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

J. Chodakewitz, J. Wagner, T. Marbury, 2009, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic Interaction of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy subjects

J. Wagner, J. Denef, J. Hoon, 2013 .

Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone

J. Wagner, J. Butterton, Hwa-ping Feng, 2014, European Journal of Clinical Pharmacology.

Biomarkers in drug development

J. Wagner, J. Delfino, Robert N. Schuck, 2022, Atkinson's Principles of Clinical Pharmacology.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

J. Holst, W. Zeng, C. Deacon, 2006, The Journal of clinical endocrinology and metabolism.

Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report

H. Soares, R. Pietrusko, V. Quarmby, 2005, Pharmaceutical Research.

Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience

John A Wagner, Qi Liu, Vadim Zipunnikov, 2020, Clinical and translational science.

Overview of Biomarkers and Surrogate Endpoints in Drug Development

John A. Wagner, J. Wagner, 2002, Disease markers.

Accelerating Drug Development Using Biomarkers: A Case Study with Sitagliptin, A Novel DPP4 Inhibitor for Type 2 Diabetes

G. Herman, J. Wagner, R. Krishna, 2008, The AAPS Journal.

Pharmacokinetics of Ertapenem in Patients With Varying Degrees of Renal Insufficiency and in Patients on Hemodialysis

P. Deutsch, S. Swan, D. Sica, 2006, Journal of clinical pharmacology.

Dental Impaction Pain Model as a Potential Tool to Evaluate Drugs With Efficacy in Neuropathic Pain

R. Ramakrishnan, J. Wagner, K. Gottesdiener, 2006, Journal of clinical pharmacology.

Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm

J. Chodakewitz, J. Wagner, K. Yee, 2009, Journal of clinical pharmacology.

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

C. Matthews, J. Wagner, K. Gottesdiener, 2010, Clinical drug investigation.

Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects

C. Matthews, J. Wagner, K. Gottesdiener, 2010, Clinical drug investigation.

THE COX-2 INHIBITOR ETORICOXIB DID NOT ALTER THE ANTI-PLATELET EFFECTS OF LOW-DOSE ASPIRIN IN HEALTHY VOLUNTEERS.

S. Waldman, W. Kraft, H. Greenberg, 2001 .

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

W. Zeng, G. Herman, A. Bergman, 2006, Journal of clinical pharmacology.

Relationship of Arachidonic Acid Concentration to Cyclooxygenase‐Dependent Human Platelet Aggregation

S. Waldman, G. Pitari, W. Kraft, 2003, Journal of clinical pharmacology.

Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects

A. Bergman, J. Wagner, K. Lasseter, 2011, Journal of clinical pharmacology.

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

W. Zeng, G. Herman, A. Bergman, 2011, British journal of clinical pharmacology.

Effect of Sitagliptin on the Pharmacokinetics of Simvastatin

G. Herman, A. Bergman, B. Keymeulen, 2009, Journal of clinical pharmacology.

Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin

N. Thornberry, G. Herman, J. Wagner, 2007, Clinical pharmacology and therapeutics.

The Effects of Multiple Doses of Rolofylline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Subjects

H. Dittrich, J. Wagner, M. Stroh, 2010, American journal of therapeutics.

Equivalent Dynamic Human Brain NK1‐Receptor Occupancy Following Single‐Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

G. Bormans, K. Van Laere, R. Hargreaves, 2012, Clinical pharmacology and therapeutics.

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy

L. Webster, E. O'Mara, J. Wagner, 2015, European Journal of Clinical Pharmacology.

Molecular Biomarkers

R. Hendrickson, O. Laterza, J. Wagner, 2007 .

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

D. Johns, J. Wagner, R. Krishna, 2012, Clinical pharmacology and therapeutics.

Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis

W. Wood, V. Zipunnikov, J. Menetski, 2021, Digital Biomarkers.

Continuous Monitoring Using a Wearable Device Detects Activity‐Induced Heart Rate Changes After Administration of Amphetamine

Elena S. Izmailova, Greg Hather, Eric D. Perakslis, 2019, Clinical and translational science.

Wearable Devices in Clinical Trials: Hype and Hypothesis

Elena S. Izmailova, Eric D. Perakslis, John A. Wagner, 2018, Clinical pharmacology and therapeutics.

Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.

Michael E. Lassman, D. Rader, M. Cleary, 2013, Rapid communications in mass spectrometry : RCM.

Differential Effects of Amiodarone and Desethylamiodarone on Calcium Antagonist Receptors

S. Snyder, H. Weisman, J. Wagner, 1990, Journal of cardiovascular pharmacology.

Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients

W. S. Denney, M. Reitman, W. Kraft, 2012, Journal of clinical pharmacology.

Biomarker Analysis as a Decision-Making Tool in Drug Discovery and Development

J. Wagner, S. Stoch, S. Stoch, 2007, International Journal of Pharmaceutical Medicine.

Early clinical development of pharmaceuticals for type 2 diabetes mellitus: from preclinical models to human investigation.

J. Wagner, 2002, The Journal of clinical endocrinology and metabolism.

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

W. Kraft, C. Matthews, J. Wagner, 2020, Clinical and translational science.

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

John A Wagner, Rajesh Krishna, Arthur J Bergman, 2007, The Lancet.

Effect of Raltegravir on the Pharmacokinetics of Methadone

J. Wagner, W. Hanley, M. Iwamoto, 2010, Journal of clinical pharmacology.

Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women

J. Wagner, M. Gutierrez, J. Schwartz, 2009, American journal of therapeutics.

Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.

C. Lines, M. Kryger, J. Wagner, 2015, Respiratory medicine.

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S]

R. Krauss, C. Pinto, J. Wagner, 2012, Journal of Lipid Research.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

W. Zeng, G. Herman, A. Bergman, 2006, Clinical Therapeutics.

A Single Supratherapeutic Dose of Rolofylline Does Not Prolong the QTcF Interval in Healthy Volunteers

J. Wagner, M. Stroh, A. Johnson‐Levonas, 2010, American journal of therapeutics.

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E[S]

Michael E. Lassman, D. Rader, H. Ginsberg, 2017, Journal of Lipid Research.

Crowdsourced Asparagus Urinary Odor Population Kinetics

Lei Zhang, P. H. van der Graaf, B. Sadler, 2017, CPT: pharmacometrics & systems pharmacology.

Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects

O. Laterza, J. Wagner, J. Schwartz, 2008, Journal of clinical pharmacology.

What Can Be Learned From Crowdsourced Population Asparagus Urinary Odor Kinetics?

J. Wagner, A. Facius, G. Lahu, 2019, CPT: pharmacometrics & systems pharmacology.

Applications of 'decisionable' biomarkers in cardiovascular drug development.

J. Wagner, R. Krishna, 2010, Biomarkers in medicine.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, The Journal of clinical investigation.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2015, The Journal of clinical investigation.

Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.

J. Wagner, M. Stroh, J. Schwartz, 2009, Cardiovascular therapeutics.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Remote digital monitoring in clinical trials in the time of COVID-19

Joseph P Menetski, John A Wagner, Elena S Izmailova, 2020, Nature Reviews Drug Discovery.

Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

W. Zeng, G. Herman, A. Bergman, 2007, Biopharmaceutics & drug disposition.

Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects

W. Zeng, G. Herman, A. Bergman, 2007, Journal of clinical pharmacology.

Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects

C. Lines, G. Zammit, J. Wagner, 2015, Journal of clinical pharmacology.

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

J. Wagner, J. Stone, T. Kakuda, 2008, Antimicrobial Agents and Chemotherapy.

A cost-effectiveness approach to the qualification and acceptance of biomarkers

John A. Wagner, Stephen A. Williams, J. Wagner, 2006, Nature Reviews Drug Discovery.

Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants

P. Deutsch, J. Wagner, J. Stone, 2011, Journal of clinical pharmacology.

Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Steady‐State Pharmacokinetics of Digoxin in Healthy Adult Subjects

J. Wagner, A. Johnson‐Levonas, L. Wenning, 2010, Journal of clinical pharmacology.

Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs – midazolam and odanacatib

R. Evers, J. Wagner, A. Mehta, 2014, Journal of clinical pharmacology.

What evidence do we need for biomarker qualification?

Chris Leptak, Joseph P Menetski, John A Wagner, 2017, Science Translational Medicine.

Opening Up to Precompetitive Collaboration

Sharyl J. Nass, Stephen H. Friend, Anna D. Barker, 2010, Science Translational Medicine.

Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation

J. Lunceford, N. Hariparsad, J. Wagner, 2011, Journal of clinical pharmacology.

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals

J. Wagner, J. Butterton, K. Yee, 2015, AIDS.

Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop

W. Jusko, H. Eichler, F. Goodsaid, 2011, The AAPS Journal.

Human Pharmacokinetics and Interconversion of Enantiomers of MK‐0767, a Dual PPARα/γ Agonist

H. Greenberg, G. Herman, J. Wagner, 2007 .

Abstract 190: A Niacin Receptor Partial Agonist, MK-0354, Robustly Reduces Plasma Free Fatty Acids and Produces Little Flushing but Fails to Alter LDL-C, HDL-C, and Triglycerides in Humans

D. Connolly, J. Paolini, J. Wagner, 2007 .

Evaluation of Wearable Digital Devices in a Phase I Clinical Trial

Elena S. Izmailova, Greg Hather, Eric D. Perakslis, 2019, Clinical and translational science.

Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.

Suzanne K. Lewis, K. Galinsky, A. Fasano, 2020, Gastroenterology.

Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go?

John A Wagner, Arthur J Bergman, J. Chodakewitz, 2011, Journal of clinical pharmacology.

Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

R. M. Stewart, D. Tarsy, J. Wagner, 2009, Journal of clinical pharmacology.

Remote Digital Monitoring for Medical Product Development

Qi Liu, John A. Wagner, Luca Foschini, 2020, Clinical and Translational Science.

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

J. Chodakewitz, W. Kraft, J. Wagner, 2010, Platelets.

Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Recreational Polydrug Users

E. Sellers, J. Chodakewitz, J. Wagner, 2012, Journal of clinical psychopharmacology.

The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction

Christopher P. Austin, John A. Wagner, P. Herrling, 2019, Clinical pharmacology and therapeutics.

Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development

Christopher P Austin, John A Wagner, Russ B Altman, 2017, Clinical and translational science.

Lack of Erectogenic Activity of a Novel Selective Melanocortin‐4 Receptor Agonist in a Clinical Experimental Model

R. Rosen, G. Herman, J. Wagner, 2008, Journal of clinical pharmacology.

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.

Molecular Biomarkers

R. Hendrickson, O. Laterza, J. Wagner, 2007 .

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects

J. Wagner, K. Yee, J. McCrea, 2015, Journal of psychopharmacology.

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

R. Nachbar, A. Hüser, E. Gane, 2018, Clinical therapeutics.

Th-W56:7 A cost-benefit approach to the regulation, qualification and acceptance of biomarkers and surrogate endpoints

Stephen A. Williams, J. Wagner, C. Webster, 2006 .

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

J. Wagner, J. Stone, W. Hanley, 2011, British journal of clinical pharmacology.

Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist.

H. Greenberg, G. Herman, J. Wagner, 2007, Journal of clinical pharmacology.

Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers

J. Chodakewitz, J. Wagner, M. Trucksis, 2009 .

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy

L. Webster, E. O'Mara, J. Wagner, 2015, European Journal of Clinical Pharmacology.

Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone

J. Wagner, J. Butterton, Hwa-ping Feng, 2014, European Journal of Clinical Pharmacology.

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design

C Gibson, X. Chu, R. Evers, 2011, Clinical pharmacology and therapeutics.

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

W. Kraft, J. Wagner, A. van Hecken, 2011, Platelets.

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

J. Wagner, D. Ebel, G. Atiee, 2010, Journal of clinical pharmacology.

Jefferson Digital

Inge, W. Kraft, J. Wagner, 2022 .

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers

J. Wagner, Yang Liu, A. Johnson‐Levonas, 2014, Journal of clinical pharmacology.

Individual and Combined Effects of Peroxisome Proliferator‐Activated Receptor α and γ Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers

Margaret S. Wu, J. Miller, D. Moller, 2005, Journal of clinical pharmacology.

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK‐0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

G. Bray, S. Heymsfield, S. Heymsfield, 2009, Clinical pharmacology and therapeutics.

Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1

J. Holst, B. Weiss, N. Thornberry, 2010, Clinical pharmacology and therapeutics.

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies

L. Duong, J. Wagner, D. Panebianco, 2009, Clinical pharmacology and therapeutics.

Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects

J. Wagner, P. De Kam, L. Wenning, 2015, American journal of therapeutics.

Multiple‐Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

D. Bloomfield, L. Bortel, O. Laterza, 2008, Clinical pharmacology and therapeutics.

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

Stephen A. Williams, J. Wagner, C. Girman, 2009, Clinical pharmacology and therapeutics.

Safety and pharmacokinetics of the novel BACE inhibitor MK-8931 in healthy subjects following single- and Multiple-Dose administration

M. Forman, L. Ereshefsky, J. Wagner, 2012, Alzheimer's & Dementia.

The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration

M. Forman, L. Ereshefsky, O. Laterza, 2012, Alzheimer's & Dementia.

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

D. Rader, D. Connolly, Jiajun Liu, 2012, Science Translational Medicine.

MK-0448, a Specific Kv1.5 Inhibitor: Safety, Pharmacokinetics, and Pharmacodynamic Electrophysiology in Experimental Animal Models and Humans

W. Kraft, H. Greenberg, C. Regan, 2012, Circulation. Arrhythmia and electrophysiology.

Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin

J. Wagner, K. Lasseter, J. Schwartz, 2008, Advances in therapy.

Lack of a Signiﬁcant Drug Interaction between Raltegravir and Tenofovir (cid:1)

H. Teppler, J. Wagner, K. Lasseter, 2008 .

Erratum: Translational biomarkers: From preclinical to clinical a report of 2009 AAPS/ACCP biomarker workshop (AAPS Journal DOI: 10.1208/s12248-011-9265-x)

W. Jusko, H. Eichler, F. Goodsaid, 2011 .

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

W. Kraft, J. Wagner, A. van Hecken, 2011, Platelets.

Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women

J. Wagner, M. Gutierrez, J. Schwartz, 2009, American journal of therapeutics.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, The Journal of clinical investigation.

Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans

D. Dean, Sanjeev Kumar, A. Bergman, 2010, Drug Metabolism and Disposition.

Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

A. Bergman, J. Wagner, R. Krishna, 2009, Journal of clinical pharmacology.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus

W. Kraft, J. Wagner, M. Trucksis, 2012, Cancer Chemotherapy and Pharmacology.

E. Sellers, J. Chodakewitz, J. Wagner, 2012, Journal of Clinical Psychopharmacology.